<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071079</url>
  </required_header>
  <id_info>
    <org_study_id>MAL21001</org_study_id>
    <nct_id>NCT05071079</nct_id>
  </id_info>
  <brief_title>A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes</brief_title>
  <acronym>MIST2</acronym>
  <official_title>A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess the safety and feasibility of blood-stage&#xD;
      controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers through&#xD;
      experimental injection of cryopreserved P. vivax infected erythrocytes, and to choose the&#xD;
      optimal inoculation dose for future P. vivax CHMI studies. In this study, blood-stage CHMI&#xD;
      will be conducted in 8 volunteers per inoculum stock who will be infected with P. vivax by&#xD;
      experimental injection with cryopreserved P. vivax infected erythrocytes, which were&#xD;
      collected from the controlled human Plasmodium vivax malaria infection model through&#xD;
      experimental sporozoite infection in Thai adults (NCT04083508) . As there are currently 2&#xD;
      stocks of inocula from 2 volunteers in the NCT04083508 study, which have different quantity&#xD;
      and stage of parasites.&#xD;
&#xD;
      The total number of volunteers of this study would be up to 16 (8 volunteers per inocula&#xD;
      stock). The volunteers will be monitored closely as in-patients in the Hospital for Tropical&#xD;
      Diseases, and will be treated according to the Research Proposal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a blood-stage P. vivax human challenge study with the primary aim of assessing&#xD;
      the safety and feasibility of a challenge model using two banks of cryopreserved P. vivax&#xD;
      infected erythrocytes produced from NCT04083508 study to identify the dose of the inocula to&#xD;
      be used in the future CHMI studies.&#xD;
&#xD;
      Sixteen healthy Thai adults, aged between 18 and 55 years will be recruited at the Clinical&#xD;
      Therapeutics Unit (CTU) in the Hospital for Tropical Diseases, Faculty of Tropical Medicine,&#xD;
      Mahidol University, Bangkok. The overall period of each volunteer's participation will be 13&#xD;
      months: 2-week screening process prior to the Day 0 challenge, about 2-week inoculum process&#xD;
      until reaching malarial treatment criteria, and follow-up period for 1 year after malarial&#xD;
      treatment. All inclusion and exclusion criteria will be checked to ensure eligibility&#xD;
      criteria have been met prior to Day 0.&#xD;
&#xD;
      Volunteers will be admitted to the hospital one day prior to challenged day. All eligible&#xD;
      volunteers will have physical examinations. Serum pregnancy test (woman only), malaria&#xD;
      diagnosis, complete blood count (CBC), and biochemistry will be tested. Glucose -6-phospate&#xD;
      dehydrogenase (G6PD) test and malaria immunological profiles will be tested for baseline&#xD;
      information.&#xD;
&#xD;
      On the challenged day (Day 0), four different doses of inoculum (one whole vial,1:5 dilution,&#xD;
      1:10 dilution, and 1:20 dilution) will be assessed. Each dose of inoculum will be tested in 2&#xD;
      volunteers to identify the lowest concentration producing a reliable infection within a&#xD;
      practicable timeframe. Therefore, there will be 8 volunteers enrolled per inoculum bank.&#xD;
&#xD;
      The assessment will be repeated in each inoculum bank. There are 2 inoculum banks so 16&#xD;
      volunteers will be enrolled into this study.&#xD;
&#xD;
      From Day 1 after challenge, the volunteers will be assessed once daily until malaria qPCR&#xD;
      becomes positive. The assessment includes a clinical well-being check, physical examination,&#xD;
      vital signs, and blood drawn for parasitaemia (malaria blood film, qPCR, and gametocyte qPCR)&#xD;
      and membrane feeding to assess the transmissibility of gametocyte. Malaria immunology and CBC&#xD;
      will be performed on day 4 and the day that qPCR become positive.&#xD;
&#xD;
      After qPCR become positive the clinical well-being will be continue. Blood will be drawn&#xD;
      twice daily to monitor blood parasitemia and membrane feeding to assess the transmissibility&#xD;
      of gametocyte. Malaria immunology, CBC, and blood biochemistry will be performed on day that&#xD;
      volunteer reach malaria treatment criteria.&#xD;
&#xD;
      A study physician will immediately prescribe malarial treatment with chloroquine according to&#xD;
      local standard guideline. Blood will be collected to test for malaria (blood films and qPCR)&#xD;
      once daily until clinically recovered and wo consecutive malaria blood films are negative&#xD;
      (completing of the chloroquine treatment course) and volunteers will be discharged from the&#xD;
      hospital.&#xD;
&#xD;
      If any volunteer reaches day 21 post-challenge without a positive malaria blood film, they&#xD;
      shall be started on 3-day course of antimalaria (chloroquine).&#xD;
&#xD;
      If a volunteer withdraws/is withdrawn from the study after challenge but before reaching the&#xD;
      criteria for malaria treatment, then a complete, appropriate, curative course of antimalarial&#xD;
      therapy must be completed&#xD;
&#xD;
      After discharge from the hospital, there will be out-patient visit on day 7, 28, 60, 90, 180,&#xD;
      and 1 year post malarial treatment initiated. Blood will be collected to detect malaria&#xD;
      parasites by blood film and qPCR, and for malaria gametocyte qPCR, membrane feeding assays&#xD;
      (MFA), malaria immune response, CBC, and biochemistry according to the study protocol.&#xD;
&#xD;
      Data analysis&#xD;
&#xD;
      The safety of the CHMI will be assessed by descriptive analysis of the frequency, incidence&#xD;
      and nature of adverse events and serious adverse events arising during the study. Since this&#xD;
      is a feasibility study conducted in 2 volunteers per dosing group, formal statistical&#xD;
      hypothesis testing will not be used for most analyses due to the limited sample size, and&#xD;
      only a brief Statistical Analysis Plan (SAP) will be developed and finalized prior to&#xD;
      database lock.&#xD;
&#xD;
      The study will be conducted in accordance with the current approved protocol, the&#xD;
      International Conference on Harmonisation-Good Clinical Practice (ICH GCP), relevant&#xD;
      regulations, and standard operating procedures. Data will be evaluated for compliance with&#xD;
      the protocol and accuracy in relation to source documents. Following written standard&#xD;
      operating procedures, the monitors will verify that the clinical study is conducted and data&#xD;
      are generated, documented and reported in compliance with the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Controlled Plasmodium vivax human malaria infection through experimental inoculation of cryopreserved infected erythrocytes in healthy Thai adults, with a randomized double blind design.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a double-blinded study; volunteers, clinical investigators, and study staff who perform laboratory study endpoint will be blinded to inoculation arm allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incident of treatment-emergent adverse events of blood-stage controlled human P. vivax malaria infection</measure>
    <time_frame>Through study completion, over one year</time_frame>
    <description>Measured by (serious) adverse event (AE) occurrences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Choosing the optimal inoculation dose for future P. vivax CHMI studies, which will be the lowest concentration that produces a reliable infection within a comparable timeframe as compare to the highest concentration.</measure>
    <time_frame>Through study completion, over one year</time_frame>
    <description>The optimal inoculation dose for future P. vivax CHMI studies, which will be the lowest concentration that produces a reliable infection within a comparable timeframe as compare to the highest concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of primary P. vivax blood-stage CHMI, as measured by successful infection (development of detectable persistent parasitaemia by thick blood film +/- clinical symptoms)</measure>
    <time_frame>Through study completion, over one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gametocytaemia stage challenge</measure>
    <time_frame>Through study completion, over one year</time_frame>
    <description>Measured by qPCR in experimental P. vivax infection through blood-stage challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmissibility of gametocytes from the infected volunteer to Anopheles mosquito vector</measure>
    <time_frame>Through study completion, over one year</time_frame>
    <description>Measured by gametocytes from the infected volunteer to Anopheles mosquito vector using Membrane feeding assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune response to primary P. vivax infection</measure>
    <time_frame>Through study completion, over one year</time_frame>
    <description>Immune cells including Innate and adaptive immune cells react and express during the PV infection (profile and frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral Immune response to primary P. vivax infection</measure>
    <time_frame>Through study completion, over one year</time_frame>
    <description>Immune cells defense PV antigen by determining the level of antibody response and inflammatory cytokine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Plasmodium Vivax Infection</condition>
  <arm_group>
    <arm_group_label>Challenge with whole dose blood-stage inoculum (neat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Challenge with 1:5 dilution blood-stage inoculum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Challenge with 1:10 dilution blood-stage inoculum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Challenge with 1:20 dilution blood-stage inoculum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum</intervention_name>
    <description>An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)</description>
    <arm_group_label>Challenge with whole dose blood-stage inoculum (neat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum</intervention_name>
    <description>An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum</description>
    <arm_group_label>Challenge with 1:5 dilution blood-stage inoculum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum</intervention_name>
    <description>An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum</description>
    <arm_group_label>Challenge with 1:10 dilution blood-stage inoculum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum</intervention_name>
    <description>An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum</description>
    <arm_group_label>Challenge with 1:20 dilution blood-stage inoculum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The volunteer must meet all of the following criteria to be eligible for the study:&#xD;
&#xD;
          1. Healthy Thai adult aged 20 to 55 years with weight at least 50 kg.&#xD;
&#xD;
          2. Red blood cells positive for the Duffy antigen/chemokine receptor (DARC)&#xD;
&#xD;
          3. Women only: Must practice continuous effective contraception for the duration of study&#xD;
             period until 3 months post-challenge.&#xD;
&#xD;
          4. Agreement to refrain from blood donation during the course of the study and for 1 year&#xD;
             after the initiation of antimalarial treatment.&#xD;
&#xD;
          5. Willing to be admitted in the Hospital for Tropical Diseases for clinical monitoring,&#xD;
             until antimalarial treatment is completed and their symptoms are settling.&#xD;
&#xD;
          6. Willing to take a curative antimalarial treatment following CHMI.&#xD;
&#xD;
          7. Willing to reside in Bangkok and its vicinity for 2 months after malarial treatment&#xD;
             initiation.&#xD;
&#xD;
          8. Able to read and write in Thai.&#xD;
&#xD;
          9. Provide written informed consent to participate in the trial&#xD;
&#xD;
         10. Answer all questions on the informed consent quiz correctly&#xD;
&#xD;
         11. Educational level: has at least an undergraduate degree&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The volunteer must NOT enter the study if any of the following apply:&#xD;
&#xD;
          1. Positive malaria qPCR OR malaria film&#xD;
&#xD;
          2. Presence of any medical condition (either physical or psychological) which in the&#xD;
             judgment of the investigator would place the participant at undue risk or interfere&#xD;
             with the results of the study (e.g. serious underlying cardiac, renal, hepatic or&#xD;
             neurological disease; severe malnutrition; congenital defects or febrile condition)&#xD;
&#xD;
          3. Presence of chronic disease or chronically use of medication&#xD;
&#xD;
          4. Use of systemic antibiotics with known antimalarial activity in the 30 days before&#xD;
             challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,&#xD;
             erythromycin, fluoroquinolones and azithromycin)&#xD;
&#xD;
          5. Use of immunoglobulins or blood products (e.g. blood transfusion) at any time in the 1&#xD;
             year preceding enrolment&#xD;
&#xD;
          6. Receipt of an investigational product, any vaccine in the 30 days preceding enrolment&#xD;
             (D0), or planned receipt during the study period&#xD;
&#xD;
          7. Prior receipt of an investigational vaccine likely to impact on interpretation of the&#xD;
             trial data or the P. vivax parasite as assessed by the Investigator.&#xD;
&#xD;
          8. Any confirmed, or suspected immunosuppressive, or immunodeficient state, including HIV&#xD;
             infection, asplenia, history of splenectomy, recurrent, severe infections, and chronic&#xD;
             infection&#xD;
&#xD;
          9. Immunosuppressant medication within the past 6 months preceding enrolment (D0)&#xD;
             (inhaled and topical steroids are allowed)&#xD;
&#xD;
         10. History of allergic disease or reactions likely to be exacerbated by malaria infection&#xD;
&#xD;
         11. Female participant who is pregnant as evidenced by positive beta-human chorionic&#xD;
             gonadotropin (β-HCG) test, lactating, or planning pregnancy during the course of the&#xD;
             study&#xD;
&#xD;
         12. Contraindications to the use of antimalarial treatment (e.g. chloroquine, atovaquone /&#xD;
             proguanil or dihydroartemisinin/piperaquine)&#xD;
&#xD;
         13. Use of medications known to have a potentially clinically significant interaction with&#xD;
             the antimalarial drug that will be used in this study (chloroquine, atovaquone /&#xD;
             proguanil or dihydroartemisinin/piperaquine)&#xD;
&#xD;
         14. Known existing positive family history in both 1st AND 2nd degree relatives &lt; 50 years&#xD;
             old for cardiac disease&#xD;
&#xD;
         15. History of cardiac arrhythmia, including clinically relevant bradycardia&#xD;
&#xD;
         16. Family history of congenital QT prolongation or sudden death&#xD;
&#xD;
         17. Any clinical condition, including using medications, known to prolong the QT interval.&#xD;
&#xD;
         18. Screening electrocardiogram (ECG) demonstrates a QT interval corrected for heart rate&#xD;
             (QTc) ≥ 450 ms.&#xD;
&#xD;
         19. Suspected or known or history of alcohol abuse&#xD;
&#xD;
         20. Suspected or known or history of drug abuse.&#xD;
&#xD;
         21. Concurrently participating in another clinical study, at any time during the study&#xD;
             period&#xD;
&#xD;
         22. Haemoglobin &lt; 11 g/dL&#xD;
&#xD;
         23. Positive hepatitis B surface antigen or seropositive for hepatitis C virus&#xD;
&#xD;
         24. Positive vector-borne diseases (dengue, chikungunya, zika, Japanese encephalitis,&#xD;
             filaria)&#xD;
&#xD;
         25. Finding on safety laboratory values as defined below:&#xD;
&#xD;
               -  Abnormal AST (AST &gt; 40 U/L for male, and &gt; 32 U/L for female [upper normal&#xD;
                  range])&#xD;
&#xD;
               -  Abnormal ALT (ALT &gt; 41 U/L for male, and &gt; 33 U/L for female [upper normal&#xD;
                  range])&#xD;
&#xD;
               -  Abnormal serum creatinine (Scr) (Creatinine [Cr] &gt; 1.17 mg/dL for male, and &gt;&#xD;
                  0.95 mg/dL for female [upper normal range])&#xD;
&#xD;
               -  Abnormal blood urea nitrogen (BUN 6-20 mg/dl [normal range])&#xD;
&#xD;
               -  Abnormalities corrected calcium and magnesium blood levels&#xD;
&#xD;
         26. Blood group Rhesus negative&#xD;
&#xD;
         27. Blood incompatibility to the inoculum&#xD;
&#xD;
         28. Positive for coronavirus disease 2019 (COVID-19)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Day, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Day, MD</last_name>
    <phone>+66 (0)2 354 9170</phone>
    <phone_ext>2020</phone_ext>
    <email>nickd@tropmedres.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jetsumon Sattabongkot Prachumsri, Ph.D</last_name>
    <phone>+66 (0)2 354 9100</phone>
    <phone_ext>2022</phone_ext>
    <email>jetsumon.pra@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Tropical Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Borimas Hanboonkunupakarn, MD</last_name>
      <phone>+66 (0)8 6 9705705</phone>
      <email>borimas@tropmedres.ac</email>
    </contact>
    <contact_backup>
      <last_name>Podjanee Jittamala, MD</last_name>
      <phone>+66 (0)8 1956 3371</phone>
      <email>podjanee@tropmedres.ac</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013 Jan;26(1):36-57. doi: 10.1128/CMR.00074-12. Review.</citation>
    <PMID>23297258</PMID>
  </reference>
  <reference>
    <citation>Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014 Dec 8;13:481. doi: 10.1186/1475-2875-13-481. Review.</citation>
    <PMID>25486908</PMID>
  </reference>
  <reference>
    <citation>Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87. Review.</citation>
    <PMID>18165478</PMID>
  </reference>
  <reference>
    <citation>Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440. doi: 10.1371/journal.pntd.0006440. eCollection 2018 Apr.</citation>
    <PMID>29677199</PMID>
  </reference>
  <reference>
    <citation>Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013 Jun 20;12:212. doi: 10.1186/1475-2875-12-212.</citation>
    <PMID>23782898</PMID>
  </reference>
  <reference>
    <citation>Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013 Oct 3;369(14):1381-2. doi: 10.1056/NEJMc1301936.</citation>
    <PMID>24088113</PMID>
  </reference>
  <reference>
    <citation>Grabowsky M. The billion-dollar malaria moment. Nature. 2008 Feb 28;451(7182):1051-2. doi: 10.1038/4511051a.</citation>
    <PMID>18305524</PMID>
  </reference>
  <reference>
    <citation>Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. Lancet. 2013 Nov 23;382(9906):1700-1. doi: 10.1016/S0140-6736(13)62238-2. Epub 2013 Nov 14.</citation>
    <PMID>24239252</PMID>
  </reference>
  <reference>
    <citation>Mueller I, Shakri AR, Chitnis CE. Development of vaccines for Plasmodium vivax malaria. Vaccine. 2015 Dec 22;33(52):7489-95. doi: 10.1016/j.vaccine.2015.09.060. Epub 2015 Oct 1. Review.</citation>
    <PMID>26428453</PMID>
  </reference>
  <reference>
    <citation>Payne RO, Griffin PM, McCarthy JS, Draper SJ. Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol. 2017 Feb;33(2):141-150. doi: 10.1016/j.pt.2016.11.001. Epub 2016 Dec 10. Review.</citation>
    <PMID>27956060</PMID>
  </reference>
  <reference>
    <citation>Keith JA, Agostini Bigger L, Arthur PA, Maes E, Daems R. Delivering the promise of the Decade of Vaccines: opportunities and challenges in the development of high quality new vaccines. Vaccine. 2013 Apr 18;31 Suppl 2:B184-93. doi: 10.1016/j.vaccine.2012.12.032. Review.</citation>
    <PMID>23598480</PMID>
  </reference>
  <reference>
    <citation>Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20.</citation>
    <PMID>23526951</PMID>
  </reference>
  <reference>
    <citation>Knezevic I, Moorthy V, Sheets R. WHO consultation on clinical evaluation of vaccines, 17-18 July 2014, WHO Headquarters, Geneva, Switzerland. Vaccine. 2015 Apr 21;33(17):1999-2003. doi: 10.1016/j.vaccine.2015.01.056. Epub 2015 Mar 4.</citation>
    <PMID>25749249</PMID>
  </reference>
  <reference>
    <citation>Stanisic DI, McCarthy JS, Good MF. Controlled Human Malaria Infection: Applications, Advances, and Challenges. Infect Immun. 2017 Dec 19;86(1). pii: e00479-17. doi: 10.1128/IAI.00479-17. Print 2018 Jan. Review.</citation>
    <PMID>28923897</PMID>
  </reference>
  <reference>
    <citation>Roestenberg M, Hoogerwerf MA, Ferreira DM, Mordmüller B, Yazdanbakhsh M. Experimental infection of human volunteers. Lancet Infect Dis. 2018 Oct;18(10):e312-e322. doi: 10.1016/S1473-3099(18)30177-4. Epub 2018 Jun 18. Review.</citation>
    <PMID>29891332</PMID>
  </reference>
  <reference>
    <citation>Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, Silk SE, Biswas S, Miura K, Roberts R, Rampling TW, Venkatraman N, Hodgson SH, Labbé GM, Halstead FD, Poulton ID, Nugent FL, de Graaf H, Sukhtankar P, Williams NC, Ockenhouse CF, Kathcart AK, Qabar AN, Waters NC, Soisson LA, Birkett AJ, Cooke GS, Faust SN, Woods C, Ivinson K, McCarthy JS, Diggs CL, Vekemans J, Long CA, Hill AV, Lawrie AM, Dutta S, Draper SJ. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis. 2016 Jun 1;213(11):1743-51. doi: 10.1093/infdis/jiw039. Epub 2016 Feb 4. Erratum in: J Infect Dis. 2016 Sep 15;214(6):978.</citation>
    <PMID>26908756</PMID>
  </reference>
  <reference>
    <citation>McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, Elliott S, Whiley D, Sloots T, Winzeler EA, Trenholme KR. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis. 2013 Nov 15;208(10):1688-94. doi: 10.1093/infdis/jit394. Epub 2013 Aug 1.</citation>
    <PMID>23908484</PMID>
  </reference>
  <reference>
    <citation>Griffin P, Pasay C, Elliott S, Sekuloski S, Sikulu M, Hugo L, Khoury D, Cromer D, Davenport M, Sattabongkot J, Ivinson K, Ockenhouse C, McCarthy J. Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Negl Trop Dis. 2016 Dec 8;10(12):e0005139. doi: 10.1371/journal.pntd.0005139. eCollection 2016 Dec.</citation>
    <PMID>27930652</PMID>
  </reference>
  <reference>
    <citation>Collins KA, Wang CY, Adams M, Mitchell H, Robinson GJ, Rampton M, Elliott S, Odedra A, Khoury D, Ballard E, Shelper TB, Lucantoni L, Avery VM, Chalon S, Moehrle JJ, McCarthy JS. A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions. J Clin Invest. 2020 Jun 1;130(6):2920-2927. doi: 10.1172/JCI134923.</citation>
    <PMID>32045385</PMID>
  </reference>
  <reference>
    <citation>Odedra A, Mudie K, Kennedy G, Watts RE, Rossignol E, Mitchell H, Gower J, Rebelo M, Pava Z, Pawliw R, Woolley S, Lalloo DG, Robinson G, Lynch S, Collins KA, Amante F, McCarthy J. Safety and feasibility of apheresis to harvest and concentrate parasites from subjects with induced blood stage Plasmodium vivax infection. Malar J. 2021 Jan 14;20(1):43. doi: 10.1186/s12936-021-03581-w.</citation>
    <PMID>33446191</PMID>
  </reference>
  <reference>
    <citation>Robinson S, Harris A, Atkinson S, Atterbury C, Bolton-Maggs P, Elliott C, Hawkins T, Hazra E, Howell C, New H, Shackleton T, Shreeve K, Taylor C. The administration of blood components: a British Society for Haematology Guideline. Transfus Med. 2018 Feb;28(1):3-21. doi: 10.1111/tme.12481. Epub 2017 Nov 6.</citation>
    <PMID>29110357</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>controlled human malaria infection</keyword>
  <keyword>Plasmodium Vivax Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Volunteer's data and results from blood analyses stored in our database may be shared with other researchers to use in the future. However, the other researchers will not be given any information that could identify the subject.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

